Research Study

News Articles for Research Study top ^

2013/2/6

Yandera Project EPC pricing received from China's NFC, Feasibility Study update and interim funding arrangement

Yandera Project EPC pricing received from China's NFC, Feasibility Study update and interim funding arrangement Canada NewsWire /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TSX: MRN ASX & POMSoX: MMC TORONTO , Feb.

View more Yandera Project EPC pricing received from China's NFC, Feasibility Study update and interim funding arrangement analysis

Sign-up for Yandera Project EPC pricing received from China's NFC, Feasibility Study update and interim funding arrangement investment picks

2013/3/4

People to People Ambassador Programs Kicks Off College Study Abroad Programs from Antarctica to India

Nationally recognized educational travel provider for students creates turnkey educational tours on three continents geared toward college students SPOKANE, Wash.

View more People to People Ambassador Programs Kicks Off College Study Abroad Programs from Antarctica to India analysis

Sign-up for People to People Ambassador Programs Kicks Off College Study Abroad Programs from Antarctica to India investment picks

2013/1/31

Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer

Company to Host Conference Call at 8:00 AM EST Today LAWRENCEVILLE, N.J. , Jan.

View more Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer analysis

Sign-up for Celsion Announces Results of Phase III HEAT Study of ThermoDox® in Primary Liver Cancer investment picks

2013/1/29

Northcliff releases positive Feasibility Study for Sisson Tungsten-Molybdenum Project

Northcliff releases positive Feasibility Study for Sisson Tungsten-Molybdenum Project Canada NewsWire Canada's bulk-tonnage Sisson mine could become the largest tungsten producer outside China VANCOUVER , Jan.

View more Northcliff releases positive Feasibility Study for Sisson Tungsten-Molybdenum Project analysis

Sign-up for Northcliff releases positive Feasibility Study for Sisson Tungsten-Molybdenum Project investment picks

2013/2/20

People to People Ambassador Programs Kicks Off College Study Abroad Programs from Antarctica to India

Nationally recognized educational travel provider for students creates turnkey educational tours on three continents geared toward college students SPOKANE, Wash.

View more People to People Ambassador Programs Kicks Off College Study Abroad Programs from Antarctica to India analysis

Sign-up for People to People Ambassador Programs Kicks Off College Study Abroad Programs from Antarctica to India investment picks

2013/5/1

Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013

LAWRENCEVILLE, N.J. , May 1, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that Professor Riccardo Lencioni , MD, FSIR, EBIR, 2013 WCIO Program Chairman and the Director of the Division of Diagnostic Imaging and Intervention at Pisa University School of Medicine in Italy and Lead European Principal Investigator for Celsion's Phase III HEAT Study and Ronnie T.P. Poon , MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the University of Hong Kong and Lead Asia Pacific Principal Investigator for Celsion's Phase III HEAT Study will, in conjunction with their scientific presentations, review the clinical trial results including new emerging findings from the HEAT Study post hoc analysis at the 9 th Annual Meeting of the World Conference on Interventional Oncology, which is being held May 16 – 20, 2013 in New York City.

View more Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013 analysis

Sign-up for Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology (WCIO) in New York City on May 16, 2013 investment picks

2013/4/26

Ford Motor Company Fund Donates $1 Million to College for Creative Studies

CCS dedicates Henry Ford Academy: School for Creative Studies College and Career Transitions Office DETROIT , April 26, 2013 /PRNewswire/ -- The College for Creative Studies (CCS) announced today that Ford Motor Company Fund will donate $1 million over five years, strengthening its commitment to one of the world's leading art and design colleges and providing educational opportunities to Detroit youth.

View more Ford Motor Company Fund Donates $1 Million to College for Creative Studies analysis

Sign-up for Ford Motor Company Fund Donates $1 Million to College for Creative Studies investment picks

2013/4/30

Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL

NEW YORK, April 30, 2013 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) , a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced additional details relating to the analysis presented by the Global Primary Biliary Cirrhosis Study Group (Study Group) at the annual meeting of the European Association for the Study of the Liver (EASL) held in Amsterdam on April 24-28, 2013.

View more Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL analysis

Sign-up for Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL investment picks

2013/3/18

MetLife Study Finds Employees Who Are Satisfied with Benefits More Likely to Recommend Employer as a “Great Place to Work”

MetLife’s 11 th Annual Study of Employee Benefits Trends, released today, reveals that while only two out of five U.S. workers would strongly recommend their employer as a “great place to work,” those who do are three times more likely to be satisfied with their benefits.

View more MetLife Study Finds Employees Who Are Satisfied with Benefits More Likely to Recommend Employer as a “Great Place to Work” analysis

Sign-up for MetLife Study Finds Employees Who Are Satisfied with Benefits More Likely to Recommend Employer as a “Great Place to Work” investment picks

2013/3/14

MetLife’s Second Stable Value Study Finds Most Plan Sponsors “Staying the Course” with Stable Value

According to MetLife’s 2013 Stable Value Study, released today, the vast majority (86%) of plan sponsors have been offering stable value as an investment option in their defined contribution (DC) plans for more than two years, and more than 78% are not planning to make changes to their stable value offerings within the next year.

View more MetLife’s Second Stable Value Study Finds Most Plan Sponsors “Staying the Course” with Stable Value analysis

Sign-up for MetLife’s Second Stable Value Study Finds Most Plan Sponsors “Staying the Course” with Stable Value investment picks

2013/3/20

ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results today from ACADIA’s pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis at the Emerging Science session of the 65 th American Academy of Neurology (AAN) Annual Meeting.

View more ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting analysis

Sign-up for ACADIA Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting investment picks

2013/2/15

Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium

CRANBURY, N.J. and ORLANDO, Fla., Feb.

View more Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium analysis

Sign-up for Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium investment picks

2013/3/21

Effect of Genzyme’s LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies

Genzyme , a Sanofi Company (EURONEXT: SAN and NYSE: SNY), announced today interim results from the first year of the extension study of LEMTRADA™ (alemtuzumab), being developed for the treatment for multiple sclerosis (MS). In this analysis of the first year of the extension study, relapse rates and sustained accumulation of disability remained low among patients who had previously received LEMTRADA in either of the Phase III CARE-MS I and CARE-MS II studies.

View more Effect of Genzyme’s LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies analysis

Sign-up for Effect of Genzyme’s LEMTRADA™ Maintained in Patients Beyond Two-Year Pivotal MS Studies investment picks

2013/4/23

High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection Canada NewsWire The study results will be presented this week at the International Liver Congress, the 48 th annual meeting of the European Association for the Study of the Liver (EASL), in Amsterdam .

View more High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection analysis

Sign-up for High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection investment picks

2013/2/21

GoGold's Parral Pre-Feasibility Study Shows Reserves of 35 Million Ounces Silver Equivalent and a Pre-tax IRR of 80%

GoGold's Parral Pre-Feasibility Study Shows Reserves of 35 Million Ounces Silver Equivalent and a Pre-tax IRR of 80% Canada NewsWire Trading Symbol: TSX: GGD Shares Issued: 128,288,331 HALIFAX , Feb.

View more GoGold's Parral Pre-Feasibility Study Shows Reserves of 35 Million Ounces Silver Equivalent and a Pre-tax IRR of 80% analysis

Sign-up for GoGold's Parral Pre-Feasibility Study Shows Reserves of 35 Million Ounces Silver Equivalent and a Pre-tax IRR of 80% investment picks

2013/2/21

Barclays Equity Gilt Study Sees Low-Risk, Low Return Environment for Investors

The ‘tail risks’ associated with the 2008-09 financial collapse have largely receded, resulting in a low-risk, low-return environment for investors who face far more challenging valuations and diminished prospective investment returns, according to the 58 th edition of the Barclays Equity Gilt Study .

View more Barclays Equity Gilt Study Sees Low-Risk, Low Return Environment for Investors analysis

Sign-up for Barclays Equity Gilt Study Sees Low-Risk, Low Return Environment for Investors investment picks

2013/2/7

J.D. Power and Associates to Release 2013 Vehicle Dependability Study Results on February 13

J.D. Power and Associates will announce the results of the 2013 Vehicle Dependability Study (VDS) at 10 a.m. EST on Wednesday, February 13 .

View more J.D. Power and Associates to Release 2013 Vehicle Dependability Study Results on February 13 analysis

Sign-up for J.D. Power and Associates to Release 2013 Vehicle Dependability Study Results on February 13 investment picks

2013/3/14

2013 RBC Canadian Water Attitudes Study: Urban-dwellers ill-prepared for impact of Mother Nature on water

2013 RBC Canadian Water Attitudes Study: Urban-dwellers ill-prepared for impact of Mother Nature on water Canada NewsWire Urban sprawl and paved paradise threaten clean fresh water today and tomorrow, says leading expert TORONTO , March 14, 2013 /CNW/ - While nine-in-10 (90 per cent) Canadians believe that an extreme weather-related disaster is possible in their community, town or city, few are aware of the consequences if excess water caused by rain and snow storms is not managed properly.

View more 2013 RBC Canadian Water Attitudes Study: Urban-dwellers ill-prepared for impact of Mother Nature on water analysis

Sign-up for 2013 RBC Canadian Water Attitudes Study: Urban-dwellers ill-prepared for impact of Mother Nature on water investment picks

2013/4/18

Widely Observed Safety Programs Used at Large Contracting Firms But Smaller Firms Lag, According to McGraw-Hill Construction Study

Industry reports insurance rates can help to accelerate adoption of more robust safety management programs NEW YORK , April 18, 2013 /PRNewswire/ -- Contractors are reporting high use of safety practices, but fully-inclusive programs are not yet taking place in smaller firms, according to a new study by McGraw-Hill Construction on safety management in the construction industry.

View more Widely Observed Safety Programs Used at Large Contracting Firms But Smaller Firms Lag, According to McGraw-Hill Construction Study analysis

Sign-up for Widely Observed Safety Programs Used at Large Contracting Firms But Smaller Firms Lag, According to McGraw-Hill Construction Study investment picks

2013/3/5

CA Technologies and Ponemon Institute Cloud Security Study Shows Improved Practices, but is Fifty Percent a Passing Grade?

CA Technologies (NASDAQ: CA) and the Ponemon Institute , an independent research firm, today released “Security of Cloud Computing Users 2013,” a study commissioned by CA Technologies that shows companies have improved their practices around cloud computing security compared to a previous study from 2010.

View more CA Technologies and Ponemon Institute Cloud Security Study Shows Improved Practices, but is Fifty Percent a Passing Grade? analysis

Sign-up for CA Technologies and Ponemon Institute Cloud Security Study Shows Improved Practices, but is Fifty Percent a Passing Grade? investment picks

Start Premium Trial

P	F	Fund Financial Data (13,000+ funds)
P	F	Stock Financial Data (7,000+ stocks)
P	F	Stock and Fund Screeners (basic)
P	F	Investing Articles and Market Commentary
P	F	Articles Archive (>30 days)
P	F	Discuss (dozens of stock, fund, bond, and general bulletin boards)
P	F	Portfolio Manager (basic)
P	F	Morningstar Investment Classroom
P	F	Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P		Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P		Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P		Morningstar Stock and Fund Stewardship Grades
P		Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P		Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P		Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P		Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P		Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P		Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.

Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.

Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.

Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.

Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.

Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.